1st is the capital infusion. While I wasn't happy with the dilution and was hopeful that organic growth could sustain us to break even and beyond I am optimistic that this raise was a clear sign of better days ahead of us. Previous Emergent patchwork raises were desperate and needed to keep the lights on moreso than fund sales growth(but still were very appreciated). I think its safe to say that Aegis got a peak under the hood and knows more than we do about the outlook of Cryoport. Would not be a prudent investment to pony up $15mm to solely provide working capital with no clear signs of near term profitability. I also don't think we would apply to uplist to Nasdaq, where short sellers can legally do what they do, and fall short on what was called a conservative estimate. If our next 2 quarters fall short and we do get uplisted, I think it will be a bloodbath.
Lastly the news in June from DHL and UPS about ramping up for impending cold chain shipping needs was very promising. As we all know we have aligned ourselves with both of these shippers and while they will also be shipping via other cold chain methods, clear signs of an increased demand bodes very well for us if we are indeed the superior solution in the space.
Market Data 
Markets 
AI
